Replies to post #134377 on Biotech Values

[mcbio]

The low rate of diarrhea and fatigue in the tivozanib phase II trial is quite impressive. These tend to be overlapping toxicities with cytotoxic chemotherapeutics, so if these results are replicated in the phase III trial then it really underscores the point that you have been making about combination therapy.

And AVEO has several combo trials involving tivo already in Phase 1 (http://www.aveopharma.com/product_candidates/ ).